Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response is consistent with the provided TREXIMET label excerpts regarding cardiovascular thrombotic risk, serious GI adverse events, relevant contraindication (CABG setting), and patient counseling. However, it also makes broader meta-assertions about boxed warnings/dosing/pregnancy/pediatrics being “not verifiable,” which are not directly supported or evaluated against specific labeling text in the provided excerpts, lowering completeness.
Category Scores
Accurate Statements
The label excerpts state that TREXIMET (sumatriptan + naproxen) is associated with increased risk of serious cardiovascular thrombotic events (including MI and stroke) (Section 5.1).
Section 5.1 cardiovascular thrombotic events excerpt.
The label excerpts state that NSAIDs including naproxen cause serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation that can be fatal (Section 5.2).
Section 5.2 gastrointestinal bleeding/ulceration/perforation excerpt.
The label includes contraindications for TREXIMET in the CABG surgery setting due to increased risk of serious cardiovascular events (Section 4 and referenced in Section 5.1).
Section 5.1 CABG/CAD contraindication excerpt and Section 4 excerpt referencing CABG setting.
The label provides risk-minimization guidance (lowest effective dose for shortest duration) and patient counseling to recognize symptoms of cardiovascular and GI events (Sections 5.1/5.2 and 17).
Section 5.1 risk-minimization excerpt; Section 5.2 strategies excerpt; Section 17 counseling excerpts.
Unsupported Statements
No boxed warning section number was referenced/verified from the provided excerpts; also no dosing/administration safety, pregnancy, or pediatric safety section numbers were referenced/verified.
The response frames these as “not verifiable” items, but it does not cite or evaluate specific label text for boxed warnings, dosing/administration safety, pregnancy, or pediatric sections. This is a completeness limitation relative to the label content beyond the provided excerpts, not a verifiable label-backed assessment.
Contradictions
Important Omissions
No explicit verification of the label’s boxed warning section content (if any) or other high-priority label sections beyond the provided excerpts (e.g., detailed dosing/administration, pregnancy, pediatric).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects key safety warnings present in the provided excerpts (serious CV thrombotic events and serious GI adverse events) and related contraindication (CABG setting), which are material safety elements. The main gap is lack of verification of other label sections not included in the excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Completeness limits: the response does not confirm boxed warning content or additional safety/dosing/pregnancy/pediatric label sections because they were not provided in the excerpts and therefore not verifiably assessed.
Suggested Improvement
Restrict conclusions to the specific excerpt-supported topics (CV thrombotic events, GI bleeding/ulceration/perforation, CABG contraindication, and counseling/risk-minimization) and avoid broader “not verifiable” statements unless directly supported by additional label text.